Patent · US Active

Erythropoietin variants

US9988427B2 · kind B2 · utility

0Cited by

7References

2Claims

0Family size

Assignee

CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN · DE

Inventors

Andreas Meisel · San Francisco, US
Josef Priller · Berlin, DE
Christel Bonnas · Berlin, DE
Ulrich Dirnagl · Berlin, DE

Key dates

Filing date	Dec 15, 2008
Grant date	Jun 5, 2018
Priority date	—
Expiry date	Dec 19, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.